Analyzing Anthera Pharmaceuticals (OTCMKTS:ANTH) and Generation Bio (NASDAQ:GBIO)

Anthera Pharmaceuticals (OTCMKTS:ANTH) and Generation Bio (NASDAQ:GBIO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Profitability

This table compares Anthera Pharmaceuticals and Generation Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anthera Pharmaceuticals	N/A	N/A	N/A
Generation Bio	-782.86%	-104.85%	-49.54%

Analyst Recommendations

This is a summary of recent recommendations for Anthera Pharmaceuticals and Generation Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthera Pharmaceuticals	0	0	0	0	0.00
Generation Bio	0	0	2	0	3.00

Generation Bio has a consensus price target of $6.50, indicating a potential upside of 1,110.20%. Given Generation Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Generation Bio is more favorable than Anthera Pharmaceuticals.

Earnings & Valuation

This table compares Anthera Pharmaceuticals and Generation Bio”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Generation Bio	$18.58 million	1.93	-$126.61 million	($2.19)	-0.25

Anthera Pharmaceuticals has higher earnings, but lower revenue than Generation Bio.

Institutional & Insider Ownership

95.2% of Generation Bio shares are held by institutional investors. 2.1% of Anthera Pharmaceuticals shares are held by insiders. Comparatively, 21.1% of Generation Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Anthera Pharmaceuticals has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500.

Summary

Generation Bio beats Anthera Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

About Generation Bio

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.